TG Therapeutics GAAP EPS of $0.14 misses by $0.21, revenue of $192.6M misses by $0.74M

• TG Therapeutics press release (TGTX): Q4 GAAP EPS of $0.14 misses by $0.21.
• Revenue of $192.6M (+78.0% Y/Y) misses by $0.74M.

2026 Financial Guidance

• Full year 2026 target total global revenue of approximately $875-$900 million, including BRIUMVI U.S. net product revenue of approximately $825 million-$850 million.
• Q1 2026 target BRIUMVI U.S. net product revenue of approximately $185 million–$190 million.
• Full-year 2026 target operating expense, defined as R&D and SG&A, of approximately $350 million excluding non-cash compensation, in addition to approximately $100 million in expenses associated with the subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs.